BioLineRx Expands Drug Pipeline with Three New Pre-Clinical Candidates for Treatment of Cancer, HIV and Inflammatory Bowel Disease.JERUSALEM -- BioLineRx Ltd., Israel's leading specialized drug development company, today announced that it has signed in-license agreements to develop and commercialize three new therapeutic product candidates. The three compounds are BL-1030, a small molecule for the treatment of Inflammatory Bowel Disease inflammatory bowel disease n. Abbr. IBD Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. ; BL-1050, a novel HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. therapeutic; and BL-2010, an innovative technology for the treatment of resistant cancer. The worldwide exclusive license agreements were signed with Rimonyx Pharmaceuticals, Ltd. of Nes Ziona, Israel for the development of BL-1030; Yissum, the technology transfer company of The Hebrew University Hebrew University of Jerusalem, at Mt. Scopus, Givat Ram, Ein Karem, and Rehovot, Israel; coeducational. First proposed in 1882, formally opened 1925. It is the world's largest Jewish university and is noted for its work on the Dead Sea Scrolls. in Jerusalem for BL-1050, and Ramot at Tel Aviv University Tel Aviv University (TAU, אוניברסיטת תל־אביב, את"א) is Israel's largest on-site university. Ltd., the technology transfer company of Tel Aviv University, and Bar Ilan Research & Development Company Ltd. (BIRAD BIRAD Breast Imaging-Reporting and Data System ), the technology transfer office of Bar Ilan University for the development of BL-2010. BioLineRx plans to develop these projects through its pre-clinical development Pre-clinical development is a stage in the development of a new drug that begins before clinical trials (testing in humans) can begin, and during which important safety and pharmacology data is collected. unit, BioLine Innovations Jerusalem, and to submit the projects for funding by the Israeli Office of the Chief Scientist Office of the Chief Scientist may refer to:
"With these candidates we are further expanding our robust pipeline of ethical pharmaceutical products for development and commercialization," said Dr. Morris C. Laster, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of BioLineRx. "BioLineRx was created to leverage expertise and resources to bring a carefully selected group of innovative technologies through pre-clinical and clinical development toward regulatory approval and marketing." BL-1030 BL-1030, developed by Rimonyx Pharmaceuticals, Ltd., is an L-selectin inhibitor that disrupts the early steps of inflammation, thereby reducing tissue damage. In chronic inflammatory disorders such as inflammatory bowel disease (IBD IBD abbr. inflammatory bowel disease Inflammatory bowel disease (IBD) Disease in which the lining of the intestine becomes inflamed. Mentioned in: Amebiasis IBD 1. ), an event that triggers inflammation causes a chain reaction that fuels the disease for long periods of time. BL-1030 represents a novel approach for treating IBD: it stops the inflammatory cycle by blocking L-selectin, which plays a key role in recruiting inflammatory cells to tissue. At present, IBD is treated with steroids and immunosuppressive drugs; however the drugs significant side effects Side effects Effects of a proposed project on other parts of the firm. limit their use for chronic diseases. Inflammatory bowel diseases, including Crohn's disease Crohn's disease: see colitis. and ulcerative colitis ulcerative colitis Inflammation of the colon, especially of its mucous membranes. The inflamed membranes develop patches of tiny ulcers, and the diarrhea contains blood and mucus. , are painful and debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction . In the United States alone over a million people suffer from IBD, and 10 to 15 people out of every 100,000 will develop IBD. The market for treatment of IBD was $1.2 billion in 2002 and is projected to reach $2.3 billion by 2011. BL-1050 Developed by researchers at the Hebrew University in Jerusalem, BL-1050 is a novel compound that prevents an HIV-infected cell from producing copies of infectious viral particles. This reduces the number of HIV particles in the bloodstream, slowing the progression of disease in the patient. The innovative treatment has the potential to significantly improve the health of HIV-infected individuals and AIDS patients. There are over 42 million HIV-infected individuals worldwide. Despite access to anti-HIV drugs, AIDS is the fifth leading cause of death in persons aged 25-44 in the United States. The number of infected people in the population is rising even though fewer people are dying of AIDS, perpetuating the public health risk. Over $10 billion are spent annually on drugs to treat HIV and AIDS. BL-2010 BL-2010, developed by researchers at Tel Aviv and Bar Ilan Universities in Israel, is a chemotherapeutic approach for treating tumors that are resistant to standard therapies, such as 5-fluorouracil (5-FU). BL-2010 reduces tumor growth in animal models with improved safety and efficacy over conventional drug therapy. BL-2010 will be developed initially for treatment of drug-resistant colorectal and pancreatic tumors, and its use will then be expanded to cancers of the breast, lung, and prostate. Colorectal and pancreatic cancers are leading causes of cancer deaths worldwide, and the treatment of both cancers is hampered by resistance to drugs such as 5-FU. Over 875,000 new cases of colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. are diagnosed worldwide each year, with annual chemotherapeutic drug sales exceeding $2 billion. More than 80,000 cases of pancreatic cancer are diagnosed worldwide each year, and as many as 80% will succumb to the disease within the first year. About BioLineRx, Ltd. Founded in 2003 by leaders in the Israeli life-sciences sector, BioLineRx is committed to bridging the gap between innovative R&D and the global pharmaceutical industry with proprietary ethical drug products. BioLineRx is focused on advancing projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universities and biotech companies to further the commercialization of promising compounds, BioLineRx enriches the pipeline of large pharmaceutical companies seeking their next blockbuster drugs. For more information, please visit www.biolinerx.com. About Rimonyx Pharmaceuticals Ltd. Rimonyx is focused on the discovery and development of novel drugs via its proprietary SMIG SMIG Salaire Minimum Interprofessionnel Garanti SMIG Southern Minnesota Internet Group (Austin, MN) SMIG Sergeant Major Instructor in Gunnery (Canadian and British Military) (Small Molecule Inhibitors of adhesion to Glycosaminoglycans) platform. The integrated SMIG platform is based on analysis of clinically-proven drugs and combines an algorithm-selected collection of compounds, drug screening and validated drug targets. The Company is developing a pipeline of drug candidates for inflammatory disorders, viral diseases, Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. and cancer. Rimonyx was founded in 2001 and is supported by the Israeli Office of the Chief Scientist and private investors. For more information, please visit www.rimonyx.com. About Ramot at Tel Aviv University Ltd. Ramot, the technology transfer company of Tel Aviv University (TAU tau n. Symbol  The 19th letter of the Greek alphabet.tau (tou), n ), seeks to strengthen the relationship between TAU's research community and the business community, and to expedite the transfer of promising new technologies from the laboratory to the market place. Ramot identifies emerging technologies ripe for commercial development, establishes patent positions, structures research and license agreements and forms R&D collaborations, joint ventures and start up companies. About BIRAD at Bar-Ilan University Bar-Ilan Research & Development Co. Ltd. was established by Bar-Ilan University in order to develop and commercialize the applied research and to transfer the technology invented by the researchers at the University. This follows the basic concept that intellectual property and other innovative developments that have a potential to be industrial products should be nurtured in a business environment. Functioning as a commercial entity, the Company can most efficiently interface between scientific and technological development at the University and the world of business and industry. About Yissum and The Hebrew University of Jerusalem Hebrew University of Jerusalem Independent university in Jerusalem, Israel, founded in 1925. The foremost university in Israel, it attracts many Jewish students from abroad; Arab students also attend. Yissum is the Technology Transfer Company of The Hebrew University of Jerusalem. Yissum's goal is to create business arrangements with industry worldwide in order to commercialize the University's intellectual property, of which it is exclusive owner. Yissum's portfolio includes over 800 registered patents in fields such as: Biotechnology, Nanotechnology, Medicine, Pharmaceuticals, Materials, Agriculture & Nutrition, Environment and Computer Sciences. For more information please visit http://www.huji.ac.il/ or http://www.yissum.co.il/. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion